Top Stories
Top Stories
Biotech and Pharma

Celgene to sell psoriasis drug Otezla for $13.4 billion to Amgen

Key Points
  • Celgene will sell its psoriasis drug Otezla for $13.4 billion in cash to Amgen
  • The sale takes Celgene a step closer to a $74-billion takeover by Bristol-Myers Squibb.
  • The company in June offered to sell Otezla to allay concerns raised by U.S. antitrust regulators, with an analyst valuing a deal for the drug at about $9 billion at the time.


Celgene will sell its psoriasis drug Otezla for $13.4 billion in cash to Amgen, taking Celgene a step closer to a $74-billion takeover by Bristol-Myers Squibb.

Bristol-Myers said on Monday it expects the deal to close by 2019 end. The company in June offered to sell Otezla to allay concerns raised by U.S. antitrust regulators, with an analyst valuing a deal for the drug at about $9 billion at the time.

The psoriasis drug brought in sales of $1.61 billion last year. Amgen said it expected Otezla sales to grow at least in the low-single digits over the next five years.

The deal for Otezla and certain related assets and liabilities is valued at $11.2 billion, net of the present value of $2.2 billion in future cash tax benefits. Bristol-Myers Squibb said it was increasing a previously planned $5 billion accelerated share buyback to $7 billion.

Its shares rose 5.2% and those of Celgene gained 3.7% in trading before the opening bell, while Amgen fell about 1%.

Next Article
Key Points
  • "When the two companies come together, we'll have two growing businesses," Caforio said in an interview with "Mad Money's" Jim Cramer.
  • "We're going to be able to launch six new medicines, potentially, in the next two years. It's going to be a great company, [will] create value for shareholders, [and will be] very good for patients," he said.
  • "I'm focused and we're focused on creating value for the long term and we're getting to work on the integration ... I believe the value of the new company will be demonstrated rapidly," he says.